|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
We recently demonstrated that transient overexpression of HS3ST2, 3B or 4 enhanced the proliferation of breast cancer MDA-MB-231 cells and promote efficient protection against pro-apoptotic stimuli.
|
30360368 |
2018 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
We recently demonstrated that transient overexpression of HS3ST2, 3B or 4 enhanced the proliferation of breast cancer MDA-MB-231 cells and promote efficient protection against pro-apoptotic stimuli.
|
30360368 |
2018 |
|
Malignant neoplasm of breast
|
0.030 |
PosttranslationalModification
|
disease |
BEFREE |
Detection of MUC1 and HS3ST2 promoter methylation status appears to be useful molecular markers for assessing the progressive state of the disease and could be helpful in discriminating breast cancer molecular subtypes.
|
28618938 |
2017 |
|
Breast Carcinoma
|
0.030 |
PosttranslationalModification
|
disease |
BEFREE |
Detection of MUC1 and HS3ST2 promoter methylation status appears to be useful molecular markers for assessing the progressive state of the disease and could be helpful in discriminating breast cancer molecular subtypes.
|
28618938 |
2017 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
This study provides the first in vitro evidence of the involvement of HS3ST2 in breast cancer cell invasion and chemosensitivity.
|
24752740 |
2014 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
This study provides the first in vitro evidence of the involvement of HS3ST2 in breast cancer cell invasion and chemosensitivity.
|
24752740 |
2014 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Patients with HS3ST2 hypermethylation in 193 node-negative stage I-II NSCLCs with a median follow-up period of 5.8 years had poor overall survival (hazard ratio = 2.12, 95% confidence interval = 1.25-3.58, P = 0.005) compared to those without HS3ST2 hypermethylation, after adjusting for age, sex, tumor size, adjuvant therapy, recurrence, and differentiation.
|
24265783 |
2013 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We evaluated the methylation status of four genes (TGFB2, SLIT2, HS3ST2, and TMEFF2) in biopsies of four groups of patients: 60 patients with sporadic CRC, 32 patients with IBD-associated neoplasia, 85 patients with IBD without associated neoplasia (20 at high risk and 65 at low risk), and 28 healthy controls.
|
22532293 |
2013 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
3-OST-2 followed by, RASSF1A showed increased levels of methylation with advanced tumor stage (P<0.05).
|
16644104 |
2007 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
A conflicting literature has recently reported that HS3ST2, 3A, 3B and 4 may exhibit either tumor-promoting or anti-oncogenic properties, depending on the model used and cancer cell phenotype.
|
29547633 |
2018 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
A conflicting literature has recently reported that HS3ST2, 3A, 3B and 4 may exhibit either tumor-promoting or anti-oncogenic properties, depending on the model used and cancer cell phenotype.
|
29547633 |
2018 |
|
Malignant tumor of cervix
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results indicate that HS3ST2 and CCNA1 genes may play important roles in HPV-induced cervical cancer and that patients with specific hypermethylated genes may have a greater risk of progressing to invasive cervical cancer.
|
25198553 |
2014 |
|
Cervix carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results indicate that HS3ST2 and CCNA1 genes may play important roles in HPV-induced cervical cancer and that patients with specific hypermethylated genes may have a greater risk of progressing to invasive cervical cancer.
|
25198553 |
2014 |
|
cervical cancer
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results indicate that HS3ST2 and CCNA1 genes may play important roles in HPV-induced cervical cancer and that patients with specific hypermethylated genes may have a greater risk of progressing to invasive cervical cancer.
|
25198553 |
2014 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Data from lymphoma and colorectal cancer samples for SNRPN (imprinted gene), FGF6 (demethylated in the cancer samples) and HS3ST2 (methylated in the cancer samples) serve as a proof of principle showing the integration of SNP data and phased DNA-methylation information into "hepitypes" and thus the analysis of DNA methylation phylogeny in the somatic evolution of cancer.
|
21750708 |
2011 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Data from lymphoma and colorectal cancer samples for SNRPN (imprinted gene), FGF6 (demethylated in the cancer samples) and HS3ST2 (methylated in the cancer samples) serve as a proof of principle showing the integration of SNP data and phased DNA-methylation information into "hepitypes" and thus the analysis of DNA methylation phylogeny in the somatic evolution of cancer.
|
21750708 |
2011 |
|
Malignant tumor of cervix
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Our data support further evaluation of HS3ST2 and CDH1 methylation as potential markers of cervical cancer and its precursor lesions.
|
17894941 |
2007 |
|
Cervix carcinoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Our data support further evaluation of HS3ST2 and CDH1 methylation as potential markers of cervical cancer and its precursor lesions.
|
17894941 |
2007 |
|
cervical cancer
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Our data support further evaluation of HS3ST2 and CDH1 methylation as potential markers of cervical cancer and its precursor lesions.
|
17894941 |
2007 |
|
Malignant neoplasm of endometrium
|
0.010 |
Biomarker
|
disease |
BEFREE |
Methylation status of KLF4 and HS3ST2 genes as predictors of endometrial cancer and hyperplastic endometrial lesions.
|
30221668 |
2018 |
|
Endometrial Hyperplasia
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
The results of the present study establish the likelihood that aberrations in KLF4 and HS3ST2 gene methylation levels are important in the development of endometrial hyperplasia and carcinoma, with hyperplasia an intermediate step between healthy and tumour tissues.
|
30221668 |
2018 |
|
Endometrial Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Methylation status of KLF4 and HS3ST2 genes as predictors of endometrial cancer and hyperplastic endometrial lesions.
|
30221668 |
2018 |
|
Epithelial ovarian cancer
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Integrated transcriptomics dataset (n = 1147) and tissue microarrays (n = 54) of HS3ST2 also related to high-methylation statuses and the EOC prognosis.
|
29732534 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Integrated transcriptomics dataset (n = 1147) and tissue microarrays (n = 54) of HS3ST2 also related to high-methylation statuses and the EOC prognosis.
|
29732534 |
2018 |
|
Carcinoma of urinary bladder, invasive
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
|
27586786 |
2016 |